Management of anemia among patients in intensive care units

Main Article Content

Eveline Margo

Abstract

Anemia is frequently encountered in critically-ill patients in the intensive care unit (ICU). Anemia may occur both at the time of admission, during treatment and after discharge from the ICU. The causes are multifactorial and include acute blood loss, blood loss from diagnostic testing and blunted red blood cell production. Blood transfusions are frequently given to patients in the ICU to treat low hemoglobin levels due to either acute blood loss or subacute anemia associated with critical illness. Although blood transfusion is a life-saving therapy, evidence suggests that it may be associated with an increased risk of morbidity and mortality. A feature of anemia of critical illness is lack of appropriate elevation of circulating erythropoietin concentrations in response to physiological stimuli. One important concern is that anemia may not be well tolerated by a critically ill patient. A number of blood conservation strategies exist that may mitigate anemia in hospital patients and limit the need for transfusion. These strategies include the use of hemostatic agents, hemoglobin substitutes and blood salvage techniques, the reduction of blood loss associated with diagnostic testing, the use of erythropoietin and the use of restrictive blood transfusion triggers. In this article we review the prevalence of anemia during critical illness specifically among patients in the ICU, and discuss the various factors that contribute to its development, the prevention and treatment of anemia by appropriate red cell transfusion and the place of erythropoietin in treatment.

Article Details

How to Cite
Margo, E. (2008). Management of anemia among patients in intensive care units. Universa Medicina, 27(2), 78–86. https://doi.org/10.18051/UnivMed.2008.v27.78-86
Section
Review Article

References

Walsh TS, Saleh EED. Anemia during critical illness. Br J Anaesth 2006; 97: 278-91

Marini JJ, Wheeler AP. Transfusion and blood component therapy. In: Critical care medicine. 3rd ed. Philadelphia : Lippincott Williams & Wilkins, 2006. p. 247-58.

Vincent JL, Baron JF, Reinhart K, Gattinoni L, Thijs L, Webb A, et al. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-507.

Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, et al. The CRIT study: Anemia and blood transfusion in the critically ill - current clinical practice in the United Stated. Crit Care Med 2004; 32: 39-52.

Napolitano LM, Corwin HL. Efficacy of red blood cell transfusion in the critically ill. Crit Care Clin 2004; 20: 255-68.

Taylor RW, O’Brien J, Trottier SJ, Manganaro L, Cytron M, Lesko MF, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006; 34: 2302-8.

Emmanuel JE, McClelland B, Page R, editors. The clinical use of blood in medicine, obstetrics, paediatrics, surgery anaesthesia, trauma & burns. Geneva: World Health Organisation; 1997.

Walsh TS, Lee RJ, Maciver C, Garrioch M, Mackirdy F, Binning AR, et al. Anemia during and at discharge from intensive care: the impact of restrictive blood transfusion practice. Intensive Care Med 2005; 32: 100-9.

Nguyen BV, Bota DP, Melot C, Vincent JL. Time course of hemoglobin concentrations in nonbleeding intensive care unit patients. Crit Care Med 2003; 31: 406-10.

Von Ahsen N, Muller C, serke S, Frei U, Eckardt KU. Important role of nondiagnostic blood loss and blunted erytropoietic response in the anemia of medical intensive care patients. Crit Care Med 1999; 27: 2630-9.

Pusparini. Peran faktor von Willebrand dalam sistem hemostasis. J Kedokter Trisakti 2000; 20: 130-8.

Scharte M, Fink MP. Red blood cell physiology in critical illness. Crit Care Med 2003; 31: 5651-7.

Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.

Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Paqliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409-17.

Hebert PC, Wells G, Martin C, Tweeddale M, Marshall J, Blajchman M, et al. Canadian survey of transfusion practices in critically ill patients. Transfusion requirements in Critical Care investigator and the Canadian Critical Care Trials Group. Crit Care Med 1998; 26: 482-7.

Brines M, Cerani A. Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-50.

Coleman T, Brines M. Recombinant human erythropoietin in critical illness: a role beyond anemia? Crit Care 2004; 8: 337-41.

Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Shapiro MJ, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288: 2827-35.

Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. for the EPO Critical Care Trials Group. Efficacy and Safety of Epoetin Alfa in Critically Ill Patients. N Engl J Med 2007; 357: 965-76.

Corwin HL, Eckardt K-U. Erythropoietin in the critically ill: what is the evidence? Nephrol Dial Transplant 2005; 20: 2605-8.